Phantomics is a medical AI company spun out of Yonsei University Severance Hospital. Our cleared products turn cardiac MRI and CT into fast, standardized, one-click analysis, and they are already used in hospitals across Korea, Asia, the U.S. and Europe. This page introduces the company to international investors and strategic partners.
Six reasons we believe Phantomics is positioned to lead AI-driven cardiovascular diagnosis.
Cardiovascular disease is the world's leading cause of death, claiming about 17.9 million lives a year according to the WHO. Cardiac MRI and CT are the most informative non-invasive tests, but long scan and reading times and scarce expertise keep them underused. Automation unlocks that capacity.
Myomics reduces cardiac MRI analysis from 30 minutes or more to a few minutes, with quantitative results standardized against reference ranges. Our methods are documented in more than 20 peer-reviewed publications with partners such as Severance Hospital, Asan Medical Center and RSNA journals.
Clearances from the U.S. FDA, Korea's MFDS (including the Class 3 approval of Angiomics ER), Japan's PMDA, Taiwan, Thailand and Malaysia, plus ISO 13485 certification, represent years of clinical and regulatory work that new entrants must repeat.
Myomics is in routine use at more than 20 tertiary hospitals in Korea and at 19 institutions abroad. Strategic agreements with GE HealthCare Korea, Siemens Healthineers, Getz Healthcare (ASEAN distribution), K-MEDI HUB and leading university hospitals extend our reach.
Beyond Myomics, Angiomics ER brings AI triage to emergency chest pain, a 10-minute non-contrast cardiac MRI protocol targets the premium health-screening market, and deep-learning models that predict future cardiac events point toward prognostic AI.
A U.S. subsidiary in Boston, Japanese PMDA approval and JRS certification, and distribution partners across Southeast Asia give Phantomics a path into the largest imaging markets, supported by Korea's TIPS global marketing and export programs.
2022
Led by Daily Partners and Bluepoint Partners.
2024
Selected for the Ministry of SMEs and Startups' Super Gap 1000+ program and the TIPS global marketing program supporting overseas expansion.
2025
Two-year support agreement with the Seoul Metropolitan Government (2025–2026).
Phantomics welcomes conversations with financial and strategic investors, distribution partners and healthcare systems. Please use the form below or write to contact@phantomics.io with "Investor inquiry" in the subject line.
Request the company presentation, schedule a call with management or ask about partnership opportunities.
This page contains forward-looking statements based on current expectations and publicly available information about Phantomics Inc. It is provided for information only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. Figures such as analysis times and accuracy are as reported by the company and its clinical partners and may vary by site and protocol.